Ferring Pharmaceuticals Acquires BioSurface Engineering Technologies
February 19, 2015
BY ANDREW VAHRADIAN, FEBRUARY 19, 2015
Ferring Pharmaceuticals entered into an agreement to acquire the assets of BioSurface Engineering Technologies Inc. (BioSET), a developer of biomimetic growth factor peptide medical devices intended to regenerate bone and improve soft tissue repair.
Under the terms of the transaction, Ferring will acquire AMPLEX and PREFIX, two phase III-ready orthobiologic product candidates in development for foot/ankle and lumbar spine respectively. Both products are based on a unique biomimetic peptide and aim to enhance the body’s own natural mechanisms of bone repair. In addition to AMPLEX and PREFIX, Ferring has also acquired a supplemental library of biomimetic peptides intended for applications in bone and tissue repair.
In 2005, Ferring launched EUFLEXXA, a sodium hyaluronate injection indicated for the treatment of knee pain brought on by osteoarthritis (OA). Since then, the company has outlined the orthopedics sector as one of its five key therapeutic segments for its growth strategy. This transaction expands and diversifies Ferring’s product portfolio by giving the company a platform to develop orthobiologic products for joint fusion and other orthopedic surgical procedures.
BioSET was formed in 2001 as a spin out of U.S. Surgical’s acquisition of InnerDyne, Inc.
AirXpanders Announces First Commercial U.S. Procedure for AeroForm® Tissue Expander System for Breast Reconstruction
January 18, 2017
US FDA grants de novo clearance to AirXpanders' AeroForm Tissue Expander System for breast reconstruction
December 26, 2016
First Patient Treated in U.S. Randomized Trial of NeoChord’s, Off-Pump, Minimally Invasive Repair for Degenerative Mitral Regurgitation
November 9, 2016